Tolerogenic dendritic cells are efficiently generated using minocyclineand dexamethasone

Collection with item attached
2017
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/486315.do
DOI
10.1038/s41598-017-15569-1
Title
Tolerogenic dendritic cells are efficiently generated using minocyclineand dexamethasone
Description
This work was supported by Basic Science Research Program through theNational Research Foundation of Korea (NRF) funded by the Ministry ofScience, ICT and future Planning (NRF-2014R1A2A1A11050881).
abstract
Tolerogenic dendritic cells (tDCs) represent a promising tool for cellular therapy against autoimmune diseases, allergies, and transplantation rejection. Numerous pharmacological agents are known to induce tDC generation. Minocycline, which has long been used as a broad-spectrum antibiotic, was recently shown to significantly increase the generation of DCs with regulatory properties. Here, we examined the effect of the combination of minocycline with dexamethasone, rapamycin, vitamin D3, and interleukin (IL)-10, which are all known inducers of tDC generation. The highest number of tDCs was generated when minocycline and dexamethasone were used together with granulocyte colony-stimulating factor (GM-SCF) and IL-4. The tolerogenicity of the minocycline/dexamethasone-conditioned tDCs was much better than or at least equal to those of the tDCs generated with either one of these agents, as assessed through in vitro phenotypic and functional assays. In addition, pretreatment with MOG35-55 peptide-pulsed minocycline/dexamethasone-conditioned tDCs significantly ameliorated the clinical signs of experimental autoimmune encephalitis induced by MOG peptide injection in a murine model. These results confirmed that tDCs with potent tolerogenic properties could be efficiently generated by the combined use of minocycline and dexamethasone, along with GM-CSF and IL-4. Our results would help in the development of ex vivo tDC-based immunotherapies.
provenance
Made available in Cube on 2018-09-28T16:04:18Z (GMT). No. of bitstreams: 0
language
English
author
Lee, Jae-Hee
Park, Chan-Su
Jang, Sundong
Kim, Ji-Wan
Kim, Sang-Hyeon
Song, Sukgil
Kim, Kyungjae
Lee, Chong-Kil
accessioned
2018-09-28T16:04:18Z
available
2018-09-28T16:04:18Z
issued
2017
citation
SCIENTIFIC REPORTS(7)
issn
2045-2322
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/486315.do
Funder
교육부
Funding Program
BK21플러스사업(0.5)
Project ID
1345274047
Jurisdiction
Rep.of Korea
Project Name
Frontier Pharmacy Leaders
rights
openAccess
type
article


Files in This Item

There are no attached files.